Yu-Wei Chen1, Alok A Khorana2. Show Affiliations » 1. Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA. 2. Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Abstract
Entities: Disease
Mesh： See more » AdultAgedAnticoagulants/therapeutic useAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useContinental Population Groups/statistics & numerical dataControl GroupsControlled Clinical Trials as TopicFemaleFollow-Up StudiesHeparin, Low-Molecular-Weight/therapeutic useHumansMaleMiddle AgedNeoplasms/drug therapyProportional Hazards ModelsPulmonary Embolism/chemically inducedPulmonary Embolism/ethnologyPulmonary Embolism/prevention & controlRiskThrombophilia/chemically inducedThrombophilia/drug therapyUnited States/epidemiologyVenous Thromboembolism/chemically inducedVenous Thromboembolism/ethnologyVenous Thromboembolism/prevention & control
Substances： See more » AnticoagulantsAntineoplastic AgentsHeparin, Low-Molecular-Weightsemuloparin
Year: 2017 PMID： 28263404 DOI： 10.1002/ajh.24712
Source DB: PubMed Journal: Am J Hematol ISSN： 0361-8609 Impact factor: 10.047